KPV is a short tripeptide made up of the amino acids lysine-proline-valine. It is derived from the C-terminal portion of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide involved in inflammation, immune regulation, pigmentation, and tissue repair.
KPV has attracted research interest because it appears to retain many of the anti-inflammatory and immunomodulatory effects of α-MSH without strongly activating melanocortin pathways associated with pigmentation. It has been studied primarily in laboratory and animal models of inflammation, wound healing, inflammatory bowel disease, colitis, dermatitis, and infection-related inflammation.
KPV is not FDA-approved for any medical indication in the United States.
KPV appears to act as an anti-inflammatory peptide through several proposed mechanisms.
Research suggests KPV may:
Unlike full-length α-MSH, KPV may exert anti-inflammatory effects without significant melanocortin receptor activation related to skin pigmentation. Most mechanistic evidence comes from laboratory and animal studies.
Published preclinical research suggests KPV may have several biologic effects.
Potential benefits may include:
These findings are promising, but KPV has not been proven effective in large human clinical trials for inflammatory bowel disease, wound healing, skin disease, autoimmune disease, or infection.
Because KPV is not FDA-approved and human safety data are limited, its complete safety profile is not established.
Potential risks may include:
Because KPV may affect inflammatory and immune signaling, caution is appropriate in patients with autoimmune disease, active infection, immune deficiency, or those taking immunosuppressive medications.
Formal contraindications have not been established because KPV is not an FDA-approved medication.
Based on current knowledge, KPV should generally be avoided or used only with physician supervision in individuals with:
Patients with inflammatory bowel disease, autoimmune disease, chronic infection, cancer history, or immune dysfunction should consult a qualified healthcare provider before considering investigational peptide therapy.
KPV is NOT FDA-approved for any medical indication in the United States.
It is not FDA-approved for:
At present, KPV remains an investigational peptide with most evidence coming from laboratory and animal research.
Human Studies
Human clinical data for KPV are limited. KPV has not been studied in large, well-controlled human trials sufficient to establish safety or efficacy for inflammatory bowel disease, wound healing, skin disease, autoimmune disease, or other proposed uses.
Most claims regarding KPV are based on preclinical studies involving cell cultures, animal models, and mechanistic research.
Animal & Preclinical Studies
Animal and laboratory studies have evaluated KPV in inflammatory and tissue-repair models.
Preclinical studies suggest KPV may:
These studies support biologic plausibility but do not prove clinical effectiveness in humans.
Inhibition of cellular and systemic inflammation in human bronchial epithelial cells by melanocorticn-related peptides: mechanism of KPV action and role of MC3R agonists
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, outdated information, or incomplete interpretations of the available scientific literature.
KPV is not FDA-approved for any medical indication in the United States. Current evidence consists primarily of laboratory and animal research, and human safety and efficacy have not been established. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# Thymosin Beta-4